Last reviewed · How we verify
RAS Inhibitors
RAS inhibitors block the renin-angiotensin system to reduce blood pressure and protect organs from hypertension-related damage.
RAS inhibitors block the renin-angiotensin system to reduce blood pressure and protect organs from hypertension-related damage. Used for Hypertension, Heart failure, Chronic kidney disease.
At a glance
| Generic name | RAS Inhibitors |
|---|---|
| Sponsor | Shenzhen Second People's Hospital |
| Drug class | ACE inhibitor or Angiotensin II receptor blocker (ARB) |
| Target | ACE enzyme or Angiotensin II Type 1 receptor (AT1R) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
RAS inhibitors work by interrupting the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance. By inhibiting angiotensin-converting enzyme (ACE inhibitors) or blocking angiotensin II receptors (ARBs), these drugs prevent vasoconstriction and aldosterone release, leading to vasodilation and reduced sodium retention. This results in lower blood pressure and reduced strain on the heart and kidneys.
Approved indications
- Hypertension
- Heart failure
- Chronic kidney disease
- Post-myocardial infarction
Common side effects
- Cough (ACE inhibitors)
- Hyperkalemia
- Dizziness
- Fatigue
- Angioedema (rare)
Key clinical trials
- Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (PHASE2)
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (PHASE1, PHASE2)
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC (PHASE1, PHASE2)
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors (PHASE1, PHASE2)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy (PHASE2)
- Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists (PHASE4)
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |